<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

PF 431396

產(chǎn)品貨號(hào)

Axon 2107 CAS [717906-29-1] MF C22H21F3N6O3SMW 506.50 Purity: 99% Soluble in DMSO Description Dual focal adhesion kinase (FAK or PTK2) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with high affinity IC50 values of 1.5 nM and 11 nM for FAK and PYK2 respectively; PF 431396 increases bone formation and protects against bone loss in ovariectomized rats References Certificates Categories Extra info L Buckbinder et al. Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc. Nat. Acad. Sci. 2007, 104(25), 10619-10624.? ? S Han et al. Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J. Biol. Chem. 2009, 19, 13193-13201.? ? DP Walker et al. Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity. Bioorg. Med. Chem. Let. 2009, 19(12), 3253-3258.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology FAK PYK2 MAPK EC 2.7.10.2 Pfizer Licensed Products Dual FAK(PTK2) and PYK2 inhibitor Chemical name N-methyl-N-(2-((2-(2-oxoindolin-5-ylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)phenyl)methanesulfonamide Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [717906-29-1] Order Size Unit Price Stock 5 mg €80.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

PF 431396

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2107

CAS [717906-29-1]

MF C22H21F3N6O3S
MW 506.50

Purity: 99%
Soluble in DMSO

PF 431396

Description

Dual focal adhesion kinase (FAK or PTK2) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with high affinity IC50 values of 1.5 nM and 11 nM for FAK and PYK2 respectively; PF 431396 increases bone formation and protects against bone loss in ovariectomized rats

L Buckbinder et al. Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc. Nat. Acad. Sci. 2007, 104(25), 10619-10624.?

S Han et al. Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J. Biol. Chem. 2009, 19, 13193-13201.?

DP Walker et al. Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity. Bioorg. Med. Chem. Let. 2009, 19(12), 3253-3258.?

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology FAK PYK2 MAPK EC 2.7.10.2 Pfizer Licensed Products

Dual FAK(PTK2) and PYK2 inhibitor

Chemical name

N-methyl-N-(2-((2-(2-oxoindolin-5-ylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)phenyl)methanesulfonamide

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[717906-29-1]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>